Vasopressin Antagonists
High-yield Verified · Oct 2026Vasopressin inserts aquaporin-2 water channels through the V2 → Gs → cAMP pathway; tolvaptan blocks the receptor, so the kidney excretes free water but not sodium. The art is raising sodium slowly enough to spare the brain.
Nursing view → administration, monitoring and patient teaching
Compare: Diuretics compared by nephron segment — site, electrolytes and acid–base →
Compare: The ADH axis compared — diabetes insipidus, SIADH and the drugs that act on V2 →
Drugs
Mechanism
Tolvaptan is a selective vasopressin V2-receptor antagonist. Less vasopressin binding to the renal V2 receptor lowers adenylate cyclase activity and intracellular cAMP, which keeps aquaporin-2 vesicles from fusing with the collecting-duct membrane. Urine water excretion and free-water clearance (aquaresis) increase, urine osmolality falls and serum sodium rises, while urinary sodium and potassium excretion are not significantly changed. In ADPKD, lower cAMP slows cyst growth and fluid secretion into cysts.
Two vasopressin receptors: V2 for water, V1 for vessels
Arginine vasopressin (AVP), the antidiuretic hormone, is made in the hypothalamus and stored in the posterior pituitary. Its V2 receptor, on the principal cells of the collecting duct, is Gs-coupled: adenylyl cyclase raises cyclic AMP, protein kinase A starts a phosphorylation cascade, and aquaporin-2 storage vesicles move into and are inserted in the apical membrane. Aquaporin-3 and aquaporin-4 sit constitutively in the basolateral membrane, so water crosses the cell and the urine is concentrated. When vasopressin falls, aquaporin-2 is internalized and the membrane becomes watertight again.
Its V1 receptors on vascular smooth muscle couple to the Gq/11–phospholipase C–IP3 pathway, release intracellular calcium and cause vasoconstriction. Without vasopressin the collecting duct is impermeable to water — which is what the antagonists recreate.
Aquaresis: water leaves, sodium stays
Tolvaptan is a selective V2 antagonist — its V2 affinity is 1.8 times that of native AVP and 29 times its affinity for V1a. With less vasopressin bound, adenylate cyclase activity and cAMP fall and aquaporin-2 vesicles stop fusing with the membrane. Urine water excretion and free-water clearance rise and urine osmolality falls, while urinary sodium and potassium excretion are not significantly changed. The vaptans therefore increase water excretion without affecting sodium excretion — an aquaresis, not a natriuresis — and serum sodium rises. Plasma vasopressin itself may rise during treatment.
Conivaptan is an intravenous dual antagonist of the V1A and V2 receptors; its main effect in hyponatremia comes from V2 antagonism in the collecting ducts, which causes aquaresis. It is labeled to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia.
Hyponatremia by volume status
Hyponatremia means total body water is in excess of total body sodium, and it is sorted by extracellular volume. In hypovolemic hyponatremia (gastrointestinal losses, diuretics, salt wasting) total body water falls less than sodium. In euvolemic hyponatremia — SIADH, hypothyroidism, adrenal insufficiency, primary polydipsia — total body water rises while sodium is stable. In hypervolemic hyponatremia (heart failure, cirrhosis, kidney failure) water rises more than sodium.
In SIADH, vasopressin stays high despite a low plasma osmolality, so excess water is absorbed; natriuretic mechanisms then excrete salt and keep the patient euvolemic without edema. The classic picture is a serum osmolality below 275 mOsm/kg with urine osmolality above 100 mOsm/kg and urine sodium above 40 mEq/L, once volume depletion, adrenal insufficiency and hypothyroidism are excluded. Small cell lung cancer, CNS disorders and drugs such as carbamazepine and SSRIs are common causes.
Vaptans fit the euvolemic and hypervolemic states, where vasopressin is driving water retention; they are contraindicated in hypovolemic hyponatremia, where removing more water would deepen the volume loss. Demeclocycline is a tetracycline whose labeled uses are infections; it can cause a nephrogenic diabetes insipidus, and it is used for SIADH only when other therapies fail, because it is nephrotoxic.
Correct too fast and the brain pays
Within about 48 hours the brain adapts to a low sodium by expelling other osmoles, so chronic hyponatremia is often asymptomatic. If sodium is then raised too quickly, the adapted cells are injured: osmotic demyelination syndrome (formerly central pontine myelinolysis). Its manifestations are typically delayed by a few days — dysarthria, dysphagia, quadriparesis, seizures, coma, and in severe cases a locked-in syndrome in which the patient is awake but can communicate only with the eyes. Chronic hyponatremia carries a much higher risk than acute; hypokalemia, liver disease, malnutrition and alcohol use add to it.
This is why the Samsca box requires starting and restarting tolvaptan in a hospital with close sodium monitoring; its label gives more than 12 mEq/L in 24 hours as an example of too-rapid correction. SIADH or a very low starting sodium makes overly rapid correction more likely, as does fluid restriction in the first day or co-administered diuretics. If sodium rises too fast, tolvaptan is stopped and hypotonic fluid considered; desmopressin or free water can be given to slow an overly rapid correction.
ADPKD: cAMP grows the cysts
Autosomal dominant polycystic kidney disease comes from mutations in PKD1 (85% of patients) or PKD2, which encode polycystin-1 and polycystin-2 of the primary cilium. Their signaling raises intracellular cAMP, which increases chloride secretion — chloride-rich fluid secretion is an essential part of cyst formation — and cAMP, raised in ADPKD models, switches on proliferative pathways in cells from ADPKD kidneys. Tolvaptan blocks vasopressin at the V2 receptor and lowers the cAMP that would otherwise stimulate cystic proliferation and growth; in cyst epithelial cells it inhibited vasopressin-stimulated cyst growth and fluid secretion.
Jynarque slows the loss of kidney function in adults at risk of rapidly progressing disease. In TEMPO 3:4 the difference in total kidney volume developed mostly in the first year, and the composite of ADPKD events was driven by fewer worsening-kidney-function and kidney-pain events, with no effect on hypertension or albuminuria. Its boxed warning is serious liver injury, so liver tests follow a fixed schedule and the drug is dispensed only through a REMS.
Comparing the drugs
One drug, two labels
| Drug | Samsca (hyponatremia) | Jynarque (ADPKD) |
|---|---|---|
| Indication | Clinically significant euvolemic or hypervolemic hyponatremia, including heart failure and SIADH | Slow kidney function decline in adults at risk of rapidly progressing ADPKD |
| Boxed warning | Start and restart in hospital; too-rapid correction → osmotic demyelination; not for ADPKD outside the REMS | Serious, potentially fatal liver injury; REMS |
| Key monitoring | Serum sodium and neurologic status, especially at the start and after dose changes | ALT, AST and bilirubin before starting, at 2 and 4 weeks, monthly for 18 months, then every 3 months |
| Fluids | No fluid restriction in the first 24 hours; drink to thirst | Drink water when thirsty, through the day and at night if awake |
| Moderate CYP3A inhibitors | Avoid | Reduce the dose |
| Liver | Limited to 30 days; avoid in underlying liver disease, including cirrhosis | Contraindicated with significant liver impairment or injury (not uncomplicated polycystic liver disease) |
Hyponatremia by volume status
| Drug | Water vs sodium | Typical causes | Vaptan? |
|---|---|---|---|
| Hypovolemic | Total body water falls less than sodium | Vomiting, diarrhea, diuretics, salt-wasting nephropathy, cerebral salt wasting, mineralocorticoid deficiency | Contraindicated |
| Euvolemic | Water rises, sodium stable | SIADH, hypothyroidism, Addison disease, primary polydipsia, drugs | Yes, when clinically significant (Samsca, conivaptan) |
| Hypervolemic | Water rises more than sodium | Heart failure, cirrhosis, kidney failure, nephrotic syndrome | Yes, when clinically significant (Samsca, conivaptan); in cirrhosis Samsca is avoided |
Labels and StatPearls classification. Conivaptan is labeled for hospitalized euvolemic and hypervolemic hyponatremia.
Pharmacokinetics
- CYP3A, almost exclusively — tolvaptan
- Tolvaptan is metabolized almost exclusively by CYP3A, and none of its 14 metabolites is pharmacodynamically active. Ketoconazole raised tolvaptan AUC 5.4-fold (strong inhibitors are contraindicated), fluconazole and grapefruit juice raised it substantially, and rifampin cut it by about 85%. Conivaptan is itself a potent mechanism-based CYP3A inhibitor — and is listed on the Jynarque label as a CYP3A inhibitor that raises tolvaptan exposure.
- The effect lags the drug level — tolvaptan
- Peak plasma levels come 2 to 4 hours after a dose, but the peak rise in sodium and urine flow comes between 4 and 8 hours; about 60% of the peak sodium effect is still present at 24 hours, when urine excretion is no longer raised.
- Protein binding and dialysis — tolvaptan
- Tolvaptan is more than 98% bound to albumin and α1-acid glycoprotein, so dialysis may not remove it after an overdose.
- Half-life and clearance — tolvaptan
- The half-life lengthens from about 3 hours at low doses to about 12 hours at high doses because absorption is prolonged; clearance is roughly halved in patients with hyponatremia of any origin. The main circulating metabolite, an oxobutyric acid with a half-life of about 180 hours, is inactive.
- Kidney function sets the response — tolvaptan
- The increases in urine flow and free-water clearance correlate with baseline GFR. Because the effect on sodium is likely lost at very low kidney function, Samsca is not recommended below a creatinine clearance of 10 mL/min, and no benefit is expected in anuria.
Uses & drug choice
- Tolvaptan (Samsca) for clinically significant hypervolemic or euvolemic hyponatremia — serum sodium below 125 mEq/L, or less marked hyponatremia that is symptomatic and has resisted fluid restriction — including patients with heart failure and SIADH
- Tolvaptan (Jynarque) to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
Adverse effects
- Thirst, polyuria, nocturia, pollakiuria
- The aquaresis itself: blocking V2 keeps aquaporin-2 out of the membrane, so dilute urine flows until intake catches up. These aquaretic effects were the most common reason for stopping Jynarque.
- Dehydration, hypovolemia and hypernatremia
- Free-water clearance rises; unless intake matches output, serum sodium and osmolality climb. Fluid restriction, diuretics or an inability to sense thirst make it worse.
- Osmotic demyelination
- A rise in sodium that outpaces the brain’s re-adaptation after chronic hyponatremia injures the adapted cells; manifestations come days later.
- Hyperkalemia
- The acute fall in extracellular fluid volume can raise serum potassium — more so with ACE inhibitors, ARBs or potassium-sparing diuretics.
- Liver injury
- Serious hepatocellular injury, generally in the first 18 months of ADPKD treatment; ALT above 3 times normal occurred in 4.9% on Jynarque versus 1.1% on placebo, and usually resolved within 1 to 4 months of stopping.
- Small reversible fall in GFR and uric acid clearance
- During treatment GFR falls by about 6–10% and uric acid clearance by 20–25%, independent of baseline kidney function; both reverse when tolvaptan is stopped.
Toxicity & antidote
An overdose produces exaggerated pharmacology: a rise in serum sodium, polyuria, thirst and dehydration or hypovolemia. There is no specific antidote. Vital signs, electrolytes, ECG and fluid status are assessed, and water and electrolytes are replaced until the aquaresis abates; dialysis may not help because tolvaptan is more than 98% protein-bound.
Interactions
Contraindications
- Hypovolemic hyponatremia (Samsca) or hypovolemia (Jynarque) — Labeled contraindication — removing more free water from a volume-depleted patient worsens the depletion.
- Inability to sense or respond to thirst — Labeled contraindication on both labels — the patient cannot drink to replace the water lost, so dehydration and hypernatremia follow.
- Strong CYP3A inhibitors (for example ketoconazole, itraconazole, ritonavir) — Labeled contraindication — tolvaptan is metabolized almost exclusively by CYP3A; ketoconazole raised its AUC 5.4-fold.
- Anuria — Labeled contraindication — a kidney that makes no urine gives no benefit.
- Hypersensitivity to tolvaptan or any component of the product — Labeled contraindication — reactions have included anaphylaxis and generalized rash.
- Samsca in ADPKD outside the FDA-approved REMS — Labeled contraindication — because of the risk of liver injury, tolvaptan for ADPKD is given only within the REMS.
- History, signs or symptoms of significant liver impairment or injury (Jynarque) — Labeled contraindication because of the risk of serious liver injury; it does not apply to uncomplicated polycystic liver disease.
- Uncorrected abnormal blood sodium (Jynarque) — Labeled contraindication — sodium abnormalities are corrected before Jynarque starts, because the drug raises free-water loss.
- Uncorrected urinary outflow obstruction — Contraindicated on the Jynarque label, and Samsca is not given in it — the surge in urine volume can cause acute retention.
- A need to raise sodium urgently because of serious neurologic symptoms use caution — Samsca should not be used — it is not a rescue treatment for severe symptomatic hyponatremia.
- Underlying liver disease, including cirrhosis use caution — Samsca is avoided because the ability to recover from liver injury may be impaired.
- Moderate CYP3A inhibitors or strong CYP3A inducers use caution — Moderate inhibitors raise tolvaptan levels substantially (avoided with Samsca; Jynarque needs a dose reduction); strong inducers lower them and are avoided.
- Hypertonic saline (Samsca) use caution — Use together is not recommended.
- Severe kidney impairment (creatinine clearance below 10 mL/min) with Samsca use caution — Not recommended — the effect on serum sodium is likely lost at very low kidney function.
- Pregnancy or breastfeeding use caution — Tolvaptan may cause fetal harm; breastfeeding is not recommended because of the risk of electrolyte abnormalities, hypotension and volume depletion in the infant.
High-yield
- Low → high — correcting chronic hyponatremia too fast
- Pons — osmotic demyelination, formerly central pontine myelinolysis
The reason Samsca is started in hospital with close sodium monitoring.
Practice questions
Q1A 64-year-old man with small cell lung cancer has a serum sodium of 121 mEq/L despite fluid restriction. He is euvolemic, with a urine osmolality of 480 mOsm/kg. He is admitted and started on tolvaptan.
Which change in his urine is expected?
- A.More sodium excreted with the extra water
- B.Less urine volume, with higher osmolality
- C.More potassium excreted
- D.More free water excreted, with sodium excretion largely unchanged
- E.Glucose appearing in the urine
Show answer
D. More free water excreted, with sodium excretion largely unchanged — Tolvaptan blocks the V2 receptor, so aquaporin-2 is not inserted and free-water clearance rises (aquaresis) while urine osmolality falls. Urinary sodium and potassium excretion are not significantly changed. Less urine with a higher osmolality is what V2 stimulation does (the desmopressin effect), and glucose in the urine is the signature of SGLT2 inhibitors.
Q2A 58-year-old woman with alcohol use disorder and malnutrition has chronic hyponatremia. Her sodium rises very rapidly over the first day of treatment. Four days later she develops slurred speech, difficulty swallowing and weakness of all four limbs.
Which mechanism best explains her new deficits?
- A.Injury to brain cells adapted to chronic hypotonicity after a rapid rise in sodium
- B.Water moving into neurons as extracellular osmolality falls
- C.Cerebral salt wasting with renal sodium loss
- D.Liver failure from the drug used to raise her sodium
- E.Ectopic vasopressin from an occult small cell lung cancer
Show answer
A. Injury to brain cells adapted to chronic hypotonicity after a rapid rise in sodium — Within about 48 hours the brain adapts to hyponatremia; raising sodium too quickly then causes osmotic demyelination, with dysarthria, dysphagia and quadriparesis typically delayed by a few days, and malnutrition and alcohol use raise the risk. Water moving into neurons (cerebral edema) is the mechanism of falling sodium, whereas hers rose; cerebral salt wasting and ectopic vasopressin are causes of hyponatremia, not of a rising sodium. Liver injury presents with fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice rather than this delayed bulbar and limb weakness.
Q3A 38-year-old man with rapidly progressing ADPKD has taken tolvaptan for 4 months. Routine monitoring shows ALT at 4 times the upper limit of normal; he feels well and no other cause is found.
What is the best next step?
- A.Continue and recheck at the next 3-monthly test
- B.Halve the dose and continue
- C.Switch to the Samsca brand of tolvaptan
- D.Add a moderate CYP3A inhibitor to lower the dose needed
- E.Stop tolvaptan, repeat liver tests within 48–72 hours, and do not restart
Show answer
E. Stop tolvaptan, repeat liver tests within 48–72 hours, and do not restart — Jynarque carries a boxed warning for serious liver injury. If ALT, AST or bilirubin rises above 2 times normal it is stopped immediately and tests are repeated within 48 to 72 hours; it is not restarted in a patient whose ALT or AST ever exceeded 3 times normal unless another cause is found and the injury has resolved. Samsca is the same drug and is not used for ADPKD outside the REMS, and a CYP3A inhibitor would raise tolvaptan exposure.
Q4A 76-year-old woman has had 3 days of vomiting and diarrhea. She is orthostatic with dry mucous membranes, and her serum sodium is 126 mEq/L. A resident suggests tolvaptan.
Why is tolvaptan contraindicated here?
- A.It causes a natriuresis that would deepen her salt loss
- B.It blocks vascular V1 receptors and would worsen her hypotension
- C.It removes free water from a patient who is already volume-depleted
- D.Vasopressin is suppressed in hypovolemia, so there is nothing to block
- E.It is excreted unchanged by the kidneys, which are underperfused
Show answer
C. It removes free water from a patient who is already volume-depleted — Hypovolemic hyponatremia is a labeled contraindication: tolvaptan’s aquaresis removes free water, deepening the volume loss; such patients are treated with isotonic fluid. Tolvaptan does not cause natriuresis — urinary sodium excretion is not significantly changed — and it is V2-selective (29 times its V1a affinity). Hypovolemia stimulates vasopressin release rather than suppressing it, and tolvaptan is cleared almost entirely by CYP3A, with less than 1% excreted unchanged in urine.
Sources
- Samsca (tolvaptan) — FDA label: boxed warning, hyponatremia indication, osmotic demyelination, liver injury, CYP3A — FDA / DailyMed
- Jynarque (tolvaptan) — FDA label: boxed warning, ADPKD indication, liver monitoring, REMS, mechanism — FDA / DailyMed
- Vaprisol (conivaptan) — FDA label: dual V1A/V2 antagonist, hospitalized euvolemic and hypervolemic hyponatremia — FDA / DailyMed
- Syndrome of Inappropriate Antidiuretic Hormone Secretion — ADH and aquaporin-2, sodium reference range — StatPearls / NCBI Bookshelf
- Autosomal Dominant Polycystic Kidney Disease — cAMP and cyst growth, tolvaptan — StatPearls / NCBI Bookshelf
- Physiology, Vasopressin — synthesis and storage, V2 receptor and aquaporin-2 — StatPearls / NCBI Bookshelf
- The use of stems in the selection of INN (stem -vaptan) — World Health Organization
- Hyponatremia — volume status, aquaporins, vaptans, correction and osmotic demyelination — StatPearls (NCBI)
- Desmopressin — the V2 receptor is Gs-coupled — StatPearls (NCBI)
- Vasostrict (vasopressin) — V1 Gq/11 and V2 adenylyl cyclase coupling (FDA label) — FDA / DailyMed
- Demeclocycline hydrochloride tablets — indications, nephrogenic diabetes insipidus (FDA label) — FDA / DailyMed
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.